GE HealthCare receives FDA approval for Flyrcado PET radiotracer, set to transform coronary artery disease diagnosis
GE HealthCare has received the US Food and Drug Administration (FDA) approval for Flyrcado (flurpiridaz F-18), a breakthrough PET radiotracer poised to transform the diagnosis of coronary artery disease (CAD). This novel radiopharmaceutical offers higher diagnostic efficacy compared to the current standard, single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). CAD remains the leading […]
